MedTrace Logo

Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma

NCT01096810 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2016-07-22

Study results available
· View outcomes & findings →

Summary

Purpose:

The purpose of this study is to see if TBL 12, which is a blend of Sea Cucumber, Sea Sponge, Shark Fin, and Sea Urchin (animals that live in the Pacific Ocean) as well as Sargassum (a plant that lives in the Pacific Ocean), will have effects against asymptomatic multiple myeloma and to see what the side effects are.

Eligibility:

Several criteria must be met to be eligible for this study, including but not limited to the following:

* a diagnosis of asymptomatic multiple myeloma
* adequate cardiac, liver and kidney function
* age 18 and older

Conditions

Interventions

DRUG

TBL 12

TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.

Sponsors & Collaborators

  • Unicorn Pacific Corporation

    collaborator INDUSTRY

  • Jagannath, Sundar, M.D.

    lead INDIV

Principal Investigators

  • Sundar Jagannath, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01096810 on ClinicalTrials.gov